Advancements in Cancer Research: Innovations and Impacts

Hilary Robbins, a prominent scientist at the World Health Organization’s International Agency for Research on Cancer (IARC), recently presented at the 2025 G7 Cancer Conference. Robbins, who holds a Master of Science in Public Health (MSPH) and a PhD in Epidemiology, leads the Risk Assessment and Early Detection (RED) Team. Her team, comprising 16 scientists from 14 countries, focuses on cancer prevention strategies. Notably, they developed a validated protein biomarker panel aimed at enhancing lung cancer screening, contributing to the Lung Cancer Cohort Consortium (LC3), which aggregates data from 3 million participants across 26 cohorts globally. Their work earned the 2024 Annals of Epidemiology Best Overall Paper Award for its innovative approach to biomarker discovery.

Alumni Spotlight: Hilary Robbins, MSPH ’12, MHS, PhD ’18Mitochondrial-targeting drug attacks cancer cells from withinmRNA Cancer Vaccines: A New Hope for Targeted Treatment (if Kennedy Doesn’t Stop the Research) – AZ Public Health Association

In parallel, research funded by the National Institutes of Health (NIH) is exploring messenger RNA (mRNA) vaccines as a novel approach to cancer treatment. These vaccines, initially developed for infectious diseases, are now being tested for their ability to train the immune system to target tumors. Over 120 clinical trials are currently assessing mRNA vaccines for various cancers, including melanoma and pancreatic cancer. Preliminary results indicate that combining mRNA vaccines with existing immunotherapy drugs could significantly lower recurrence rates in melanoma patients. However, this promising research faces potential setbacks due to political opposition, particularly from figures like Robert F. Kennedy Jr., who has expressed intentions to halt mRNA research.

mRNA Cancer Vaccines: A New Hope for Targeted Treatment (if Kennedy Doesn’t Stop the Research) – AZ Public Health AssociationMitochondrial-targeting drug attacks cancer cells from withinShorter, Less Intense Radiation-Chemo Regimen Effective for HPV-Linked Oropharyngeal Cancer, Mayo Study Shows

A recent study from the Mayo Clinic has introduced a less intensive regimen of radiation and chemotherapy for patients with HPV-positive oropharyngeal squamous cell carcinoma. This new approach, which follows minimally invasive surgery, significantly reduces treatment-related side effects while maintaining high cure rates. The study demonstrated that a two-week course of gentler radiation therapy, known as the de-escalated regimen of adjuvant radiotherapy (DART), resulted in fewer severe toxicities compared to standard treatments. This research is particularly relevant given the rising incidence of HPV-related cancers and the need for effective yet less harmful treatment options.

Shorter, Less Intense Radiation-Chemo Regimen Effective for HPV-Linked Oropharyngeal Cancer, Mayo Study ShowsMitochondrial-targeting drug attacks cancer cells from withinmRNA Cancer Vaccines: A New Hope for Targeted Treatment (if Kennedy Doesn’t Stop the Research) – AZ Public Health AssociationDenmark close to wiping out leading cancer-causing HPV strains after vaccine roll-out

Denmark has reported a significant reduction in infections from the two primary cancer-causing strains of human papillomavirus (HPV) since the introduction of the HPV vaccine in 2008. The prevalence of HPV types 16 and 18 has dropped from 15-17% to less than 1% among vaccinated women by 2021. This decline suggests a potential shift in cervical cancer screening protocols as vaccinated populations age. However, challenges remain, as unvaccinated women still show a 5% prevalence of these high-risk HPV types, indicating the need for continued vigilance in public health strategies.

Denmark close to wiping out leading cancer-causing HPV strains after vaccine roll-outmRNA Cancer Vaccines: A New Hope for Targeted Treatment (if Kennedy Doesn’t Stop the Research) – AZ Public Health AssociationShorter, Less Intense Radiation-Chemo Regimen Effective for HPV-Linked Oropharyngeal Cancer, Mayo Study ShowsAlumni Spotlight: Hilary Robbins, MSPH ’12, MHS, PhD ’18

Researchers at the Medical University of South Carolina (MUSC) have developed a new drug, LCL768, which targets head and neck cancers by disrupting mitochondrial function in cancer cells. This innovative compound increases levels of C18-ceramide, leading to cancer cell death through a process called mitophagy. Early preclinical studies show promise, suggesting that LCL768 could provide a safer alternative to traditional chemotherapy and radiation, which often harm healthy tissues. The research team is optimistic about advancing LCL768 toward clinical trials, potentially offering new hope for patients with treatment-resistant cancers.

Mitochondrial-targeting drug attacks cancer cells from withinmRNA Cancer Vaccines: A New Hope for Targeted Treatment (if Kennedy Doesn’t Stop the Research) – AZ Public Health AssociationShorter, Less Intense Radiation-Chemo Regimen Effective for HPV-Linked Oropharyngeal Cancer, Mayo Study Shows

These advancements in cancer research highlight a multifaceted approach to combating various types of cancer, from innovative treatments and vaccines to improved screening methods. As research continues to evolve, the integration of these findings into clinical practice could significantly enhance patient outcomes and quality of life.

mRNA Cancer Vaccines: A New Hope for Targeted Treatment (if Kennedy Doesn’t Stop the Research) – AZ Public Health Association